247 related articles for article (PubMed ID: 20953137)
1. Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2.
Wu X; Shi J; Wu Y; Tao Y; Hou J; Meng X; Hu X; Han Y; Jiang W; Tang S; Zangari M; Tricot G; Zhan F
Cancer Biol Ther; 2010 Dec; 10(11):1201-14. PubMed ID: 20953137
[TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL.
Liu Q; Hilsenbeck S; Gazitt Y
Blood; 2003 May; 101(10):4078-87. PubMed ID: 12531793
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide induces p53-dependent apoptotic signals in myeloma cells with SiRNA-silenced p53: MAP kinase pathway is preferentially activated in cells expressing inactivated p53.
Kircelli F; Akay C; Gazitt Y
Int J Oncol; 2007 Apr; 30(4):993-1001. PubMed ID: 17332940
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide selectively induces early and extensive apoptosis via the APO2/caspase-8 pathway engaging the mitochondrial pathway in myeloma cells with mutant p53.
Akay C; Gazitt Y
Cell Cycle; 2003; 2(4):358-68. PubMed ID: 12851490
[TBL] [Abstract][Full Text] [Related]
5. Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways.
Lunghi P; Giuliani N; Mazzera L; Lombardi G; Ricca M; Corradi A; Cantoni AM; Salvatore L; Riccioni R; Costanzo A; Testa U; Levrero M; Rizzoli V; Bonati A
Blood; 2008 Sep; 112(6):2450-62. PubMed ID: 18583568
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide mediates intrinsic and extrinsic pathways of apoptosis and cell cycle arrest in acute megakaryocytic leukemia.
Lam HK; Li K; Chik KW; Yang M; Liu VC; Li CK; Fok TF; Ng PC; Shing MM; Chuen CK; Yuen PM
Int J Oncol; 2005 Aug; 27(2):537-45. PubMed ID: 16010437
[TBL] [Abstract][Full Text] [Related]
7. TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt.
Szegezdi E; Cahill S; Meyer M; O'Dwyer M; Samali A
Br J Cancer; 2006 Feb; 94(3):398-406. PubMed ID: 16434995
[TBL] [Abstract][Full Text] [Related]
8. Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.
Cholujova D; Bujnakova Z; Dutkova E; Hideshima T; Groen RW; Mitsiades CS; Richardson PG; Dorfman DM; Balaz P; Anderson KC; Jakubikova J
Br J Haematol; 2017 Dec; 179(5):756-771. PubMed ID: 29048129
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation.
Li Y; Qu X; Qu J; Zhang Y; Liu J; Teng Y; Hu X; Hou K; Liu Y
Cancer Lett; 2009 Nov; 284(2):208-15. PubMed ID: 19457607
[TBL] [Abstract][Full Text] [Related]
10. Effects of arsenic trioxide alone and in combination with bortezomib in multiple myeloma RPMI 8266 cells.
Elmahi AY; Niu C; Li W; Li D; Wang GJ; Hao SS; Cui JW
Asian Pac J Cancer Prev; 2013; 14(11):6469-73. PubMed ID: 24377552
[TBL] [Abstract][Full Text] [Related]
11. P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells.
Wen J; Cheng HY; Feng Y; Rice L; Liu S; Mo A; Huang J; Zu Y; Ballon DJ; Chang CC
Br J Haematol; 2008 Jan; 140(2):169-80. PubMed ID: 18173754
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase.
Yoda A; Toyoshima K; Watanabe Y; Onishi N; Hazaka Y; Tsukuda Y; Tsukada J; Kondo T; Tanaka Y; Minami Y
J Biol Chem; 2008 Jul; 283(27):18969-79. PubMed ID: 18482988
[TBL] [Abstract][Full Text] [Related]
13. Reactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosis.
Morales AA; Gutman D; Cejas PJ; Lee KP; Boise LH
J Biol Chem; 2009 May; 284(19):12886-95. PubMed ID: 19279006
[TBL] [Abstract][Full Text] [Related]
14. Sustained activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxide-induced cell apoptosis in multiple myeloma cell lines.
Kajiguchi T; Yamamoto K; Iida S; Ueda R; Emi N; Naoe T
Cancer Sci; 2006 Jun; 97(6):540-5. PubMed ID: 16734734
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide and paclitaxel induce apoptosis by different mechanisms.
Akay C; Thomas C; Gazitt Y
Cell Cycle; 2004 Mar; 3(3):324-34. PubMed ID: 14726646
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation.
Kim EH; Yoon MJ; Kim SU; Kwon TK; Sohn S; Choi KS
Cancer Res; 2008 Jan; 68(1):266-75. PubMed ID: 18172319
[TBL] [Abstract][Full Text] [Related]
17. Proteomic and functional analyses reveal a dual molecular mechanism underlying arsenic-induced apoptosis in human multiple myeloma cells.
Ge F; Lu XP; Zeng HL; He QY; Xiong S; Jin L; He QY
J Proteome Res; 2009 Jun; 8(6):3006-19. PubMed ID: 19364129
[TBL] [Abstract][Full Text] [Related]
18. Increased growth-inhibitory and cytotoxic activity of arsenic trioxide in head and neck carcinoma cells with functional p53 deficiency and resistance to EGFR blockade.
Boyko-Fabian M; Niehr F; Distel L; Budach V; Tinhofer I
PLoS One; 2014; 9(6):e98867. PubMed ID: 24927258
[TBL] [Abstract][Full Text] [Related]
19. Improved apoptotic cell death in drug-resistant non-small-cell lung cancer cells by tumor necrosis factor-related apoptosis-inducing ligand-based treatment.
Gatti L; Cossa G; Tinelli S; Carenini N; Arrighetti N; Pennati M; Cominetti D; De Cesare M; Zunino F; Zaffaroni N; Perego P
J Pharmacol Exp Ther; 2014 Mar; 348(3):360-71. PubMed ID: 24345465
[TBL] [Abstract][Full Text] [Related]
20. Berbamine, a novel nuclear factor kappaB inhibitor, inhibits growth and induces apoptosis in human myeloma cells.
Liang Y; Xu RZ; Zhang L; Zhao XY
Acta Pharmacol Sin; 2009 Dec; 30(12):1659-65. PubMed ID: 19960011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
